Gains in childhood cancer survival slow

02/19/2013 | Bloomberg Businessweek

Although the five-year survival rate of children with cancer increased from 30% in the 1960s to 80% in the 2000s, improvement has leveled off, physicians wrote in Lancet Oncology. The report's authors say the approach to research and regulation must be modernized to address the issue. Just 15 childhood cancer drugs have been allowed for use in children since 1998.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC